On October 25, 2021 Cardinal Health (NYSE: CAH) reported its cancer screening offerings from FUJIFILM Healthcare Americas Corporation and Polymedco that can be done either outside of a doctor’s office or with less invasive procedures can help combat the increase in cancer-related deaths due to late-stage diagnoses1 from pandemic-related delays (Press release, Cardinal Health, OCT 25, 2021, View Source [SID1234591892]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. (PRNewsfoto/Cardinal Health)
"The pandemic has changed the landscape of traditional diagnostic methods and is driving the healthcare industry to evaluate screenings differently," added Chris Kerski, general manager and senior vice president of Cardinal Health Laboratory Products. "We’re adding new testing solutions to our portfolio to reduce barriers to screening and support patient-led cancer screenings."
Colon Cancer
According to a report in JAMA Oncology2, nearly 10 million cancer screenings for breast, colon and prostate cancer were missed in the U.S. since the pandemic began. Researchers recently reported a more than 40% decline in colon cancer diagnoses alone during the pandemic, a statistic that points to missed screenings, not fewer cases3.
"A missed screening increases the likelihood of a late-stage cancer diagnosis, which is associated with poor prognosis," says Nicholas Sullivan, Ph.D., a senior product manager at Cardinal Health Laboratory Products with a background in cancer biology and clinical laboratory medicine. "This high number of missed screenings during the pandemic has the potential to impact cancer patient outcomes for years."
During the pandemic, some health systems and health plans began proactively mailing screening collection kits to patients, rather than waiting for patients to come in for a routine visit or colonoscopy4. Cardinal Health works with Polymedco to offer OC-AutoFIT, which detects small amounts of blood in stool – an early indication of colon cancer5. Different than a colonoscopy, patients don’t have to prep in advance of the test and can do the stool specimen collection at home.
Liver Cancer
Liver cancer is one of the top-three leading causes of cancer-related deaths worldwide6 accounting for more than 700,000 deaths each year7.
In November 2020, Cardinal Health became the first distributor of Fujifilm’s innovative solution, the µTASWako i30 Immunoanalyzer System testing for liver biomarkers AFP-L3 and DCP using a simple blood draw. These biomarkers aid in the risk assessment of patients with chronic liver disease for the development of hepatocellular carcinoma (HCC), the most common type of liver cancer8.
HCC surveillance is critical for those at-risk for liver cancer given its lethality. A recent study9 reported that liver cancer surveillance dramatically declined during the pandemic and that "a delay of just a few months in HCC surveillance may be catastrophic for patients, given that the doubling time for HCC tumor volume is 85.7 days." Only 20% of those patients at risk of developing liver cancer receive surveillance10.
Cardinal Health now offers Fujifilm’s automated solution to enhance clinical lab customers’ liver surveillance cancer programs.
Cancer screening access
As a trusted advisor to the clinical laboratory market, Cardinal Health advocates for the important role diagnostic testing plays in improving healthcare.
"These critical expansions of our cancer screening offerings, coupled with our robust anatomic pathology and laboratory kitting services, underscore our commitment to making healthcare more accessible for patients. We must stay vigilant in preventative care through the utilization of easy-to-access screening tools and draw more awareness to the secondary impacts of the pandemic," says Kerski.